Hannu Järveläinen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hannu Järveläinen has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Annele Sainio
Institute of Biomedicine, University of Turku, Turku, Finland
7 shared publications - Heli Ylä‐Outinen
Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland; Department of Pulmonary Diseases, Turku University Hospital, Turku, Finland
2 shared publications - Juha Peltonen
Institute of Biomedicine University of Turku Turku Finland
2 shared publications Marie C. Nyman
Medical Biochemistry and Genetics, Institute of Biomedicine, University of Turku, Turku, Finland
2 shared publicationsMikko Valtanen
Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland; Department of Mathematics and Statistics, University of Turku, Turku, Finland; Department of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland
2 shared publications- Niina Loponen
Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland; FICAN West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland
2 shared publications
Latest Publications
- Open Access
- 25 May 2026
- Published by MDPI AG in Preprints.org
Telomere Dysfunction and Extracellular Matrix Remodeling
Telomeres and the extracellular matrix (ECM) are often studied as distinct contributors to aging and chronic diseases, yet growing evidence suggests they are deeply interconnected. This review explores the relationship between these two systems in both directions. Telomere shortening, shelterin defects, and loss of telomerase activity can promote senescence, stress responses, myofibroblast transition, and progressive matrix deposition. In turn, stiffness of the ECM, collagen-rich environments, and hyaluronan-linked signaling can shape telomerase activity, proliferative capacity, and telomere-associated damage responses. We bring together evidence from genetic mouse models, mechanistic cell-based studies, and human tissue analyses across the lung, kidney, vasculature, and heart to examine how telomere dysfunction and ECM remodeling influence one another during aging and disease progression. We focus on epithelial cells, fibroblasts, smooth muscle cells, and tubular cells, and discuss key pathways linking telomere biology and ECM regulation, including TRF1, TERT, TGF-β, cGAS–STING, VCAM-1, and mechanotransduction signaling. Taken together, the current findings suggest that telomere dysfunction is not only a marker of tissue aging but it is also an active driver of persistent ECM remodeling and fibrosis, while signals from the ECM can in turn influence telomere maintenance and cellular senescence. This bidirectional relationship provides a clearer framework for understanding how age-related cellular damage progresses into chronic tissue scarring.
- 25 May 2026
- Published by MDPI AG in Preprints.org
Open AccessTelomere Dysfunction and Extracellular Matrix Remodeling
Telomeres and the extracellular matrix (ECM) are often studied as distinct contributors to aging and chronic diseases, yet growing evidence suggests they are deeply interconnected. This review explores the relationship between these two systems in both directions. Telomere shortening, shelterin defects, and loss of telomerase activity can promote senescence, stress responses, myofibroblast transition, and progressive matrix deposition. In turn, stiffness of the ECM, collagen-rich environments, and hyaluronan-linked signaling can shape telomerase activity, proliferative capacity, and telomere-associated damage responses. We bring together evidence from genetic mouse models, mechanistic cell-based studies, and human tissue analyses across the lung, kidney, vasculature, and heart to examine how telomere dysfunction and ECM remodeling influence one another during aging and disease progression. We focus on epithelial cells, fibroblasts, smooth muscle cells, and tubular cells, and discuss key pathways linking telomere biology and ECM regulation, including TRF1, TERT, TGF-β, cGAS–STING, VCAM-1, and mechanotransduction signaling. Taken together, the current findings suggest that telomere dysfunction is not only a marker of tissue aging but it is also an active driver of persistent ECM remodeling and fibrosis, while signals from the ECM can in turn influence telomere maintenance and cellular senescence. This bidirectional relationship provides a clearer framework for understanding how age-related cellular damage progresses into chronic tissue scarring.
- Open Access
- 21 April 2026
- Published by Springer Nature in Virology Journal
- Vol. 23 (1)
Reduction of angiogenesis in chorioallantoic membrane xenografted hepatocellular carcinomas by treatment with a decorin-expressing herpes simplex virus vector
Decorin is a proteoglycan that suppresses tumor growth and angiogenesis. We studied whether our recently constructed decorin-expressing herpes simplex virus (HSV) vector can reduce angiogenesis in xenografted liver carcinoma cells in the chorioallantoic membrane model. The vascularized tumors were treated with an overlay dose of our vector. The results show that the treatment reduced angiogenesis in the tumors by 60% ( p = 0.005) four days after treatment, suggesting that decorin-expressing HSV vectors are a promising strategy for novel cancer therapies.
- 21 April 2026
- Published by Springer Nature in Virology Journal
- Vol. 23 (1)
Open AccessReduction of angiogenesis in chorioallantoic membrane xenografted hepatocellular carcinomas by treatment with a decorin-expressing herpes simplex virus vector
Decorin is a proteoglycan that suppresses tumor growth and angiogenesis. We studied whether our recently constructed decorin-expressing herpes simplex virus (HSV) vector can reduce angiogenesis in xenografted liver carcinoma cells in the chorioallantoic membrane model. The vascularized tumors were treated with an overlay dose of our vector. The results show that the treatment reduced angiogenesis in the tumors by 60% ( p = 0.005) four days after treatment, suggesting that decorin-expressing HSV vectors are a promising strategy for novel cancer therapies.
- Open Access
- 23 August 2025
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (11) , 101571
Risk and prognosis of myocardial infarction in patients with neurofibromatosis type 1: Evidence of compromised survival
- 23 August 2025
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (11) , 101571
Open AccessRisk and prognosis of myocardial infarction in patients with neurofibromatosis type 1: Evidence of compromised survival
- Open Access
- 26 September 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 180, 117453
Empagliflozin attenuates hypoxia-induced heart failure of zebrafish embryos via influencing MMP13 expression
- 26 September 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 180, 117453
Open AccessEmpagliflozin attenuates hypoxia-induced heart failure of zebrafish embryos via influencing MMP13 expression
- Open Access
- 22 December 2023
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (1) , e2346
Hypertension in NF1: A closer look at the primacy of essential hypertension versus secondary causes
Background: We aimed to analyze hypertension in neurofibromatosis type 1 (NF1) in a Finnish population‐based cohort in 1996–2014.Methods: A cohort of 1365 individuals with confirmed NF1 was compared with a control cohort of 13,923 individuals matched for age, sex, and area of residence. Diagnoses of hypertension were retrieved from the Finnish Care Register for Health Care. These registered data were separately analyzed for secondary and essential hypertension. Purchases of antihypertensive drugs were queried from the Finnish Register of Reimbursed Drug Purchases.Results: We identified 115 NF1 patients with hospital diagnosis of hypertension. Our findings revealed a hazard ratio (HR) of 1.64 (95% CI 1.34–2.00, p < 0.001) in NF1 versus controls. NF1 patients presented with a significantly increased hazard for both secondary hypertension (n = 9, HR 3.76, 95% CI 1.77–7.95, p < 0.001) and essential hypertension (n = 98, HR 1.73, 95% CI 1.39–2.14, p < 0.001). No difference in the HR of hypertension was observed between men and women, while NF1 patients with essential hypertension were, on average, younger than the controls. The proportions of individuals with antihypertensive medication did not differ between NF1 patients and controls (OR 0.85).Conclusion: NF1 is a risk factor for hypertension. Despite the recognized risk for secondary hypertension, essential hypertension is the predominant type in NF1.
- 22 December 2023
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (1) , e2346
Open AccessHypertension in NF1: A closer look at the primacy of essential hypertension versus secondary causes
Background: We aimed to analyze hypertension in neurofibromatosis type 1 (NF1) in a Finnish population‐based cohort in 1996–2014.Methods: A cohort of 1365 individuals with confirmed NF1 was compared with a control cohort of 13,923 individuals matched for age, sex, and area of residence. Diagnoses of hypertension were retrieved from the Finnish Care Register for Health Care. These registered data were separately analyzed for secondary and essential hypertension. Purchases of antihypertensive drugs were queried from the Finnish Register of Reimbursed Drug Purchases.Results: We identified 115 NF1 patients with hospital diagnosis of hypertension. Our findings revealed a hazard ratio (HR) of 1.64 (95% CI 1.34–2.00, p < 0.001) in NF1 versus controls. NF1 patients presented with a significantly increased hazard for both secondary hypertension (n = 9, HR 3.76, 95% CI 1.77–7.95, p < 0.001) and essential hypertension (n = 98, HR 1.73, 95% CI 1.39–2.14, p < 0.001). No difference in the HR of hypertension was observed between men and women, while NF1 patients with essential hypertension were, on average, younger than the controls. The proportions of individuals with antihypertensive medication did not differ between NF1 patients and controls (OR 0.85).Conclusion: NF1 is a risk factor for hypertension. Despite the recognized risk for secondary hypertension, essential hypertension is the predominant type in NF1.
- Open Access
- 17 October 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 156, 113882
Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos
- 17 October 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 156, 113882
Open AccessDistinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos
- Open Access
- 1 February 2020
- Published by Elsevier in Cellular Signalling
- Vol. 66, 109487
Extracellular matrix-cell interactions: Focus on therapeutic applications
- 1 February 2020
- Published by Elsevier in Cellular Signalling
- Vol. 66, 109487
Open AccessExtracellular matrix-cell interactions: Focus on therapeutic applications
- Open Access
- 22 April 2019
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 67 (7) , 511-522
Decorin Expression in Human Vulva Carcinoma: Oncosuppressive Effect of Decorin cDNA Transduction on Carcinoma Cells
The extracellular matrix proteoglycan decorin is well-known for its oncosuppressive activity. Here, decorin expression was examined in human vulva carcinoma tissue samples and in primary and commercial cell lines representing this malignant disease. Furthermore, the effect of adenovirus-mediated decorin cDNA (Ad-DCN) transduction on the viability, proliferation, and the expression and activity of the epidermal growth factor receptor (ErbB/HER) family members of the cell lines were investigated. Using in situ hybridization and immunohistochemistry for decorin, it was demonstrated that malignant cells in human vulva carcinoma tissues lack decorin expression. This result was true independently on tumor stage, grade or human papillomavirus status. RT-qPCR analyses showed that the human vulva carcinoma cell lines used in this study were also negative for decorin expression. Transduction of the cell lines with Ad-DCN caused a marked reduction in cell viability, while the proliferation of the cells was not affected. Experiments examining potential mechanisms behind the oncosuppressive effect of Ad-DCN transduction revealed that ErbB2/HER2 expression and activity in carcinoma cells were markedly downregulated. In conclusion, the results of this study showed that human vulva carcinoma cells lack decorin expression, and that Ad-DCN transduction of these cells induces oncosuppressive activity in part via downregulation of ErbB2/HER2.
- 22 April 2019
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 67 (7) , 511-522
Open AccessDecorin Expression in Human Vulva Carcinoma: Oncosuppressive Effect of Decorin cDNA Transduction on Carcinoma Cells
The extracellular matrix proteoglycan decorin is well-known for its oncosuppressive activity. Here, decorin expression was examined in human vulva carcinoma tissue samples and in primary and commercial cell lines representing this malignant disease. Furthermore, the effect of adenovirus-mediated decorin cDNA (Ad-DCN) transduction on the viability, proliferation, and the expression and activity of the epidermal growth factor receptor (ErbB/HER) family members of the cell lines were investigated. Using in situ hybridization and immunohistochemistry for decorin, it was demonstrated that malignant cells in human vulva carcinoma tissues lack decorin expression. This result was true independently on tumor stage, grade or human papillomavirus status. RT-qPCR analyses showed that the human vulva carcinoma cell lines used in this study were also negative for decorin expression. Transduction of the cell lines with Ad-DCN caused a marked reduction in cell viability, while the proliferation of the cells was not affected. Experiments examining potential mechanisms behind the oncosuppressive effect of Ad-DCN transduction revealed that ErbB2/HER2 expression and activity in carcinoma cells were markedly downregulated. In conclusion, the results of this study showed that human vulva carcinoma cells lack decorin expression, and that Ad-DCN transduction of these cells induces oncosuppressive activity in part via downregulation of ErbB2/HER2.
- 1 January 2018
- Published by Elsevier
- Vol. 81, 209-240
Extracellular Matrix Macromolecules as Potential Targets of Cardiovascular Pharmacotherapy
- 1 January 2018
- Published by Elsevier
- Vol. 81, 209-240
Extracellular Matrix Macromolecules as Potential Targets of Cardiovascular Pharmacotherapy
- Open Access
- 26 June 2017
- Published by Springer Nature in Cancer Microenvironment
- Vol. 10 (1-3) , 39-48
Human Metaplastic Breast Carcinoma and Decorin
Metaplastic breast carcinoma (MBC) is a rare subtype of invasive breast cancer and has poor prognosis. In general, cancers are heterogeneous cellular masses comprised of different cell types and their extracellular matrix (ECM). However, little is known about the composition of the ECM and its constituents in MBC. Decorin is a ubiquitous ECM macromolecule known of its oncosuppressive activity. As such, it provides an intriguing molecule in the development of novel therapeutics for different malignancies such as MBC. In this study, decorin immunoreactivity and the effect of adenoviral decorin cDNA (Ad-DCN) transduction were examined in MBC. Multiple immunohistochemical stainings were used to characterize a massive breast tumour derived from an old woman. Furthermore, three-dimensional (3D) explant cultures derived from the tumour were transduced with Ad-DCN to study the effect of the transduction on the explants. The MBC tumour was shown to be completely negative for decorin immunoreactivity demonstrating that the malignant cells were not able to synthesize decorin. Ad-DCN transduction resulted in a markedly altered cytological phenotype of MBC explants by decreasing the amount of atypical cells and by inhibiting cell proliferation. The results of this study support approaches to develop new, decorin-based adjuvant therapies for MBC.
- 26 June 2017
- Published by Springer Nature in Cancer Microenvironment
- Vol. 10 (1-3) , 39-48
Open AccessHuman Metaplastic Breast Carcinoma and Decorin
Metaplastic breast carcinoma (MBC) is a rare subtype of invasive breast cancer and has poor prognosis. In general, cancers are heterogeneous cellular masses comprised of different cell types and their extracellular matrix (ECM). However, little is known about the composition of the ECM and its constituents in MBC. Decorin is a ubiquitous ECM macromolecule known of its oncosuppressive activity. As such, it provides an intriguing molecule in the development of novel therapeutics for different malignancies such as MBC. In this study, decorin immunoreactivity and the effect of adenoviral decorin cDNA (Ad-DCN) transduction were examined in MBC. Multiple immunohistochemical stainings were used to characterize a massive breast tumour derived from an old woman. Furthermore, three-dimensional (3D) explant cultures derived from the tumour were transduced with Ad-DCN to study the effect of the transduction on the explants. The MBC tumour was shown to be completely negative for decorin immunoreactivity demonstrating that the malignant cells were not able to synthesize decorin. Ad-DCN transduction resulted in a markedly altered cytological phenotype of MBC explants by decreasing the amount of atypical cells and by inhibiting cell proliferation. The results of this study support approaches to develop new, decorin-based adjuvant therapies for MBC.